UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

Clinical pharmacokinetics, 2010-02, Vol.49 (2), p.71-87

2010

Volltextzugriff (PDF)

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Journal of clinical oncology, 2020-11, Vol.38 (31), p.3592-3603

2020

Volltextzugriff (PDF)

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer

British journal of clinical pharmacology, 2022-08, Vol.88 (8), p.3922-3923

2022

Volltextzugriff (PDF)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Clinical pharmacokinetics, 2019-04, Vol.58 (4), p.431-449

2019

Volltextzugriff (PDF)

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

Clinical pharmacokinetics, 2023-08, Vol.62 (8), p.1063-1079

2023

Volltextzugriff (PDF)

A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors

Journal of clinical pharmacology, 2023-05, Vol.63 (5), p.583-592

2023

Volltextzugriff (PDF)

Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study

Clinical pharmacology and therapeutics, 2023-08, Vol.114 (2), p.413-422

2023

Volltextzugriff (PDF)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

Clinical pharmacokinetics, 2021-02, Vol.60 (2), p.235-247

2021

Volltextzugriff (PDF)

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development

Journal of clinical pharmacology, 2022-04, Vol.62 (4), p.555-567

2022

Volltextzugriff (PDF)

Model vs. experiment to predict crop losses

Science (American Association for the Advancement of Science), 2018-12, Vol.362 (6419), p.1122-1122

2018

Volltextzugriff (PDF)

Dose Titration of Ixazomib Maintenance Therapy in Transplant‐Ineligible Multiple Myeloma: Exposure–Response Analysis of the TOURMALINE‐MM4 Study

Clinical pharmacology and therapeutics, 2023-07, Vol.114 (1), p.220-229

2023

Volltextzugriff (PDF)

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study

Clinical pharmacology and therapeutics, 2022-08, Vol.112 (2), p.327-334

2022

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

Clinical pharmacokinetics, 2017-11, Vol.56 (11), p.1355-1368

2017

Volltextzugriff (PDF)

The effect of grapefruit juice on drug disposition

Expert opinion on drug metabolism & toxicology, 2011-03, Vol.7 (3), p.267-286

2011

Volltextzugriff (PDF)

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Investigational new drugs, 2024-08, Vol.42 (4), p.343-352

2024

Volltextzugriff (PDF)

Coronary Microvascular Dysfunction Is Related to Abnormalities in Myocardial Structure and Function in Cardiac Amyloidosis

JACC. Heart failure, 2014-08, Vol.2 (4), p.358-367

2014

Volltextzugriff (PDF)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Investigational new drugs, 2023-06, Vol.41 (3), p.402-410

2023

Volltextzugriff (PDF)

Mobocertinib: Mechanism of action, clinical, and translational science

Clinical and translational science, 2024-03, Vol.17 (3), p.e13766-n/a

2024

Volltextzugriff (PDF)

Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.450-462

2013

Volltextzugriff (PDF)

Effect of severe renal impairment on the pharmacokinetics of brigatinib

Investigational new drugs, 2021-10, Vol.39 (5), p.1306-1314

2021

Volltextzugriff (PDF)

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

CPT: pharmacometrics and systems pharmacology, 2024-04, Vol.13 (4), p.624-637

2024

Volltextzugriff (PDF)

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

Journal of clinical pharmacology, 2016-10, Vol.56 (10), p.1288-1295

2016

Volltextzugriff (PDF)

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Journal of hematology and oncology, 2017-07, Vol.10 (1), p.137-13, Article 137

2017

Volltextzugriff (PDF)

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

British journal of haematology, 2016-09, Vol.174 (5), p.748-759

2016

Volltextzugriff (PDF)

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer

CPT: pharmacometrics and systems pharmacology, 2022-06, Vol.11 (6), p.731-744

2022

Volltextzugriff (PDF)

1 – 25 von 1.319

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.030)
Mit Volltextzugriff
(1.100)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.313)
Japanisch
(103)
Deutsch
(5)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(723)
Life Sciences & Biomedicine
(643)
Humans
(448)
Female
(226)
Male
(209)
Biological And Medical Sciences
(176)
Animals
(143)
Medical Sciences
(122)
Middle Aged
(117)
Adult
(109)
Cardiovascular System & Cardiology
(101)
Aged
(94)
Cardiac & Cardiovascular Systems
(72)
Fundamental And Applied Biological Sciences. Psychology
(64)
Pharmacology & Pharmacy
(63)
Physical Sciences
(59)
General & Internal Medicine
(57)
Surgery
(54)
Neurosciences & Neurology
(53)
Retrospective Studies
(53)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors

Response‐Based Dosing for Ponatinib: Model‐Based Analyses of the Dose‐Ranging OPTIC Study

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development

Model vs. experiment to predict crop losses

Dose Titration of Ixazomib Maintenance Therapy in Transplant‐Ineligible Multiple Myeloma: Exposure–Response Analysis of the TOURMALINE‐MM4 Study

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

The effect of grapefruit juice on drug disposition

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

Coronary Microvascular Dysfunction Is Related to Abnormalities in Myocardial Structure and Function in Cardiac Amyloidosis

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Mobocertinib: Mechanism of action, clinical, and translational science

Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers

Effect of severe renal impairment on the pharmacokinetics of brigatinib

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer

Suchergebnisse filtern